Influence of treatment on morphological features of mucosal inflammation

Gut

Volumn 50, Issue SUPPL. 3, 2002, Pages

  Geboes, Karel ^a   Dalle, I ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOSPORIN; GLUCOCORTICOID; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID;

CONFERENCE PAPER; DISEASE ACTIVITY; ENTERITIS; ERADICATION THERAPY; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MICROSCOPY; MUCOSA INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; SCORING SYSTEM; ULCERATIVE COLITIS;

EID: 0036104086     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.suppl_3.iii37     Document Type: Conference Paper

References (85)

1. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease?
2. Colitis, problems in definition and diagnosis
3. Is rectal biopsy necessary in irritable bowel syndrome?
4. Biopsy diagnosis of colitis. Possibilities and pitfalls
5. Observer variation and discriminatory value of biopsy features in inflammatory bowel disease
6. What is colitis? Statistical approach to distinguishing clinically important inflammatory changes in rectal biopsy specimens
7. Clinical, biological, and histological parameters as predictors of relapse in ulcerative colitis
8. A Quantitative method of estimating inflammation in the rectal mucosa. II. Normal limits in symptomatic patients
9. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease
10. Does quantitative histology of rectal biopsy improve the differential diagnosis of Crohn's disease and ulcerative colitis in adults?
11. A prospective study of first attacks of inflammatory bowel disease and infectious colitis
12. Histopathology differentiates acute self-limited colitis from ulcerative colitis
13. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: Diagnostic implications
14. An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn' disease and ulcerative colitis
15. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease
16. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease
17. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
18. Development of a Crohn's disease activity index
19. A simple index of Crohn's disease activity
20. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index
21. Cortisone in ulcerative colitis: Final report on a therapeutic trial
22. Development and validation of an endoscopic index of the severity of Crohn's disease: A prospective multicentre study
23. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis
24. Non-systemic steroids as enemas in the treatment of ulcerative colitis
25. From inflammation to lesion
26. A quantitative method of estimating inflammation in the rectal mucosa. III. Chronic ulcerative colitis
27. A quantitative method of estimating inflammation in the rectal mucosa. IV. Ulcerative colitis in remission
28. Ulcerative colitis: Patterns of involvement in colorectal biopsies and changes with time
29. Rectal mucosal plasma cells in inflammatory bowel disease
30. Colorectal biopsy in inflammatory bowel disease
31. Histological changes following intravenous cyclosporin in the treatment of refractory severe ulcerative colitis may mimic dysplasia
32. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas
33. Patchiness of mucosal inflammation in treated ulcerative colitis: A prospective study
34. Relationships between drug regime and histology of rectal mucosa in CD
35. Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial
36. Glucocorticoid treatment in ileal Crohn's disease: Relief of symptoms but not of endoscopically viewed inflammation
37. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease
38. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease
39. Response to drug therapy in Crohn's disease. Evaluation by rectal biopsy and mucosal cell counts
40. Diagnostic histopathologique de l'activité des maladies inflammatoires chroniques de l'intestin: Evaluation de l'effet des traitements médicamenteux, application des scores histologiques
41. 5-Amino-salicylic acid (5-ASA) enemas are effective in patients with resistent ulcerative colitis
42. Tumor necrosis factor α antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis
43. Measurements of disease activity
44. Colonic biopsy in inflammatory bowel disease
45. Interpretation of large intestinal mucosal biopsy specimens
46. Leucocyte migration in acute chronic inflammatory bowel disease: Comparison of histological assessment and TC-99m-HMPAO labeled leucocyte scan
47. Quantification of inflammatory bowel disease activity using technetium-99m HMPAO labeled leucocyte single photon emission computerized tomography (SPECT)
48. Correlation of histopathologic evidence of disease activity with the presence of immunoglobulin-containing cells in the colons of patients with inflammatory bowel disease
49. Morphologic and functional effects of bile salt on the porcine colon during injury and repair
50. Immune-mediated cytotoxicity in inflammatory bowel disease
51. Circulating and tissue eosinophils
52. In situ comparison of phenotypical and functional activity of infiltrating cells in ulcerative colitis mucosa
53. The role of activated T lymphocytes in gastrointestinal disease
54. Immunohistologic basis for IBD
55. Biopsy studies in ulcerative colitis
56. Correlation between defined sigmoidoscopic appearances and other measurements of disease activity in ulcerative colitis
57. Histologic and colonoscopic assessment of disease extension in ulcerative colitis
58. Relationship between disease activity and colonoscopic findings in patients with colonic inflammatory bowel disease
59. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis
60. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse
61. Microscopic activity in ulcerative colitis: What does it mean?
62. Beclomethasone diproprionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg/2g) as retention enemas in active ulcerative proctitis
63. Cyclosporin as initial treatment for Crohn's disease
64. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease
65. The endoscopic picture reflects transmural inflammation better than endoscopic biopsy in Crohn's disease
66. Early lesions caused by infusion of intestinal contents in excluded ileum in Crohn's disease
67. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
68. Endoscopy in inflammatory bowel disease: Indications and differential diagnosis
69. Survey of the use of colonoscopy in inflammatory bowel disease
70. The role of endoscopy in inflammatory bowel disease
71. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets
72. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis
73. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis
74. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis
75. Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591
76. Réversibilité des lésions histologiques
77. Grading and scoring in histopathology
78. Anti-CD4 therapy decreases epithelial expression of HLA-DR molecules in patients with Crohn's disease
79. Infliximab (anti-TNF antibody) induces histologic remission without increase of epithelial cell proliferation
80. Decreased mucosal lymphocyte proliferation following treatment with infliximab in Crohn's disease
81. Serial biopsy in ulcerative colitis